Close Menu

Galena Biopharma

NEW YORK (GenomeWeb News) – Galena Biopharma and Leica Biosystems today announced a deal for the development of a companion diagnostic for Galena's therapeutic for breast cancer.

With Marina Biotech's back against the wall, the RNAi drugs field may soon see the departure of its third player this year, following the bankruptcy of Traversa Therapeutics and the acquisition of Tacere Therapeutics by Benitec Biopharma.

RXi Pharmaceuticals this week released its second-quarter financial results, posting a surge in losses tied to its spinout from former parent firm Galena Biopharma (GSN

Galena Biopharma, the former parent firm of RXi Pharmaceuticals, has settled four lawsuits filed by investor groups that had raised questions about its now-completed spinout of the RNAi drug developer.

Galena Biopharma late last month completed its spinout of RNAi drugs subsidiary RXi Pharmaceuticals, ending a year-long saga that included an acquisition, litigation, and a management shakeup that included the loss of RXi's CSO.

Galena Biopharma said this week that it has taken the “final steps” to complete its planned spinout of RNAi subsidiary RXi Pharmaceuticals.

Galena Biopharma this week said that it has taken steps to end a dispute with investors that threatened to block the company's planned spinout of RNAi subsidiary RXi Pharmaceuticals.

Pages

The US Food and Drug Administration is to announce stricter standards for emergency authorizations of SARS-CoV-2 vaccines, reports the Washington Post.

The Associated Press reports Johnson & Johnson is starting a late-stage clinical trial of its candidate SARS-CoV-2 vaccine.

Bloomberg reports the budget of Operation Warp Speed is actually $18 billion, higher than the number typically cited.

In Genome Research this week: genomic analysis reveals role of super-spreaders in SARS-CoV-2, epigenetic drivers of cancer, and more.